Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Other hematologic neoplasm 3Dermatologic 2CNS 2Thoracic 1Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Leukemia, Myeloid, Acute 3

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ADI PEG20 × Other hematologic neoplasm × Clear all
NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Polaris Group

Phase 1 Active not recruiting
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01910012 2020-10-01

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Polaris Group

Phase 2 Completed
43 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02875093 2020-03-05

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Polaris Group

Phase 1 Terminated
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡